Amid efficacy row, Covaxin gets thumbs-up from Lancet

Amid a raging controversy over the efficacy of Covaxin, India’s first indigenous Covid-19 vaccine, reputed medical journal the Lancet Infectious Diseases on Friday said the vaccine produced tolerable safety outcomes and enhanced immune responses in its Phase 1 trials.